Dyadic International, Inc. (DYAI)
| Market Cap | 38.99M +16.7% |
| Revenue (ttm) | 3.81M +7.1% |
| Net Income | -7.29M |
| EPS | -0.21 |
| Shares Out | 36.44M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 154,735 |
| Open | 1.065 |
| Previous Close | 1.060 |
| Day's Range | 1.060 - 1.166 |
| 52-Week Range | 0.655 - 1.600 |
| Beta | 1.15 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 11, 2026 |
About DYAI
Dyadic International, Inc., together with its subsidiaries, a biotechnology platform company, develops, manufactures, and commercializes proteins and enzymes in the United States. The company offers Dapibus Protein Production Platform, a proprietary expression system designed to produce non-animal proteins and enzymes for non-pharmaceutical markets, including life sciences, food and nutrition, and bio-industrial sector; and C1 Protein Production Platform, a thermophilic fungal platform for large-scale production of proteins. It has a research a... [Read more]
Financial Performance
In 2025, Dyadic International's revenue was $3.09 million, a decrease of -11.59% compared to the previous year's $3.50 million. Losses were -$7.36 million, 26.8% more than in 2024.
Financial StatementsNews
Dyadic Develops Stable C1 Cell Lines and Produces Purified Scripps-Designed Bundibugyo Ebola Antigens from Plasmids in Approximately 15 Days
JUPITER, Fla., July 28, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (Nasdaq: DYAI) (“Dyadic” or the “Company”), d/b/a Dyadic Applied BioSolutions, today announced that, within approximately 15...
Dyadic International regains compliance with Nasdaq
Dyadic International (DYAI) announced that Nasdaq has confirmed that the company has regained compliance with Nasdaq Listing Rules 5550 and 5550. The company’s common stock continues to be listed and…
Dyadic Announces Continued Listing on the Nasdaq Capital Market
JUPITER, Fla., July 24, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (Nasdaq: DYAI) (“Dyadic” or the “Company”), d/b/a Dyadic Applied BioSolutions, a biotechnology company developing recombinan...
Dyadic expands bio-industrial pipeline with new industrial enzyme program
Dyadic International (DYAI) announced the expansion of its bio-industrial pipeline with a new proprietary industrial enzyme program focused on advanced cellulose processing. “We see this program as a ...
Dyadic Expands Bio industrial Pipeline with New Proprietary Industrial Enzyme Program
JUPITER, Fla., July 16, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (Nasdaq: DYAI) ("Dyadic" or the "Company"), d/b/a Dyadic Applied BioSolutions, a biotechnology company developing recombinan...
Global Collaborations Continue to Validate Dyadic's C1 Platform and Expands Commercial Potential
Global Collaborations Continue to Validate Dyadic's C1 Platform and Expand Commercial Opportunity Dyadic's Ebola preparedness work highlights C1's potentia
Dyadic International allowed claims by Japan Patent Office
Dyadic International (DYAI) announced that the Japan Patent Office has allowed claims covering its proprietary Thermothelomyces heterothallica recombinant protein expression technology. The Japan Pate...
Dyadic Expands IP Protection and Business Development Activities in Japan
JUPITER, Fla., June 29, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (Nasdaq: DYAI) (“Dyadic” or the “Company”), d/b/a Dyadic Applied BioSolutions, a biotechnology company focused on the develo...
An Interview with the President & COO: How Dyadic is Commercializing Its Protein Platform Across Multi-Billion-Dollar Markets
SmallCaps Daily Sits Down with Joe Hazelton to Discuss Dyadic's Product Strategy, Strategic Partnerships, and Long-Term Growth Vision New York, New York--(Newsfile Corp. - June 22, 2026) - Dyadic Appl...
Dyadic International Transcript: AGM 2026
The meeting covered approval of all shareholder proposals, including a reverse stock split and director election. Strategic updates highlighted commercial growth, new partnerships, and ongoing Nasdaq compliance efforts. Shareholders were invited to participate in a Q&A session.
Dyadic International Proxy statement: Proxy filing
Dyadic International filed a proxy statement on June 18, 2026, providing details for shareholder voting and corporate governance matters.
Dyadic Highlights Accelerated Interest in C1 Biomanufacturing Platform Amid Ebola Preparedness Activities and Growing Commercial Adoption
JUPITER, Fla., June 15, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (Nasdaq: DYAI), d/b/a Dyadic Applied BioSolutions (“Dyadic” or the “Company”), a biotechnology company focused on the develo...
Dyadic International Transcript: Lytham Partners Spring 2026 Investor Conference
Transitioning to a commercial stage, the company has launched six products in the past year and established global distribution and key partnerships, driving early revenues across life sciences, food, and bioindustrial markets. Recurring revenues and further launches are expected in 2026.
Dyadic International, Scripps Research team to evaluate Hantavirus vaccine
Dyadic International (DYAI) announced that Dyadic Applied BioSolutions and researchers at Scripps Research are collaborating to evaluate monoclonal antibody and vaccine candidates targeting hantavirus...
Dyadic and Scripps Research Collaborate on Rapid-Response Hantavirus Antibody and Vaccine Development
JUPITER, Fla., May 28, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic,” “we,” “us,” “our,” or the “Company”) (NASDAQ: DYAI), d/b/a Dyadic Applied BioSolutions, a biotechnology company fo...
Dyadic to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026
JUPITER, Fla., May 21, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), d/b/a Dyadic Applied BioSolutions, a global biotechnology com...
Skyline Corporate Communications Group, LLC Announces Dyadic Applied BioSolutions to Deliver a Live Presentation at the Skyline Signature Series™ on Wednesday, May 27 at 12:00 PM ET
Company invites individual and institutional investors, as well as advisors and analysts, to attend this real-time, interactive presentation at the Skyline Signature Series™ Company invites individual...
Dyadic International Transcript: Sidoti Micro-Cap Virtual Conference
The company has transitioned to a product-driven model, commercializing six animal-free protein products across life sciences, food nutrition, and bioindustrial markets. Strategic partnerships, scalable platforms, and a diversified revenue model support rapid growth, with recurring revenues expected to accelerate as products move from pilot to commercial scale.
Dyadic Applied BioSolutions Announces Participation in Sidoti Virtual Investor Conference
JUPITER, Fla., May 19, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic,” “we,” “us,” “our,” or the “Company”) (NASDAQ: DYAI), d/b/a Dyadic Applied BioSolutions, a global biotechnology com...
Dyadic International Slides: Investor presentation
Dyadic International has posted slides in relation to its latest quarterly earnings report, which was published on May 19, 2026.
Dyadic International Earnings Call Transcript: Q1 2026
Revenue grew 182% year-over-year to $1.1 million, driven by product launches and expanded partnerships. Loss from operations improved, and cash runway extends into Q2 2027. Commercial momentum is building across life sciences, food, and industrial segments.
Dyadic International Earnings release: Q1 2026
Dyadic International released its Q1 2026 earnings on May 13, 2026, summarizing the period's financial results.
Dyadic International Quarterly report: Q1 2026
Dyadic International has published its Q1 2026 quarterly earnings report on May 13, 2026.
Dyadic Announces First Quarter 2026 Financial Results and Highlights Recent Company Progress
Received initial purchase orders for recombinant bovine transferrin from customers in the cultivated meat industry Commercial launch of AlbuFree™ DX recombinant human albumin by Proliant Health & Biol...
Dyadic International Proxy statement: Proxy filing
Dyadic International filed a proxy statement on May 12, 2026, providing details for shareholder voting and corporate governance matters.